*May 2025* Scientists behind the phase III randomized, controlled AENEAS2 clinical trial said their results point to a new front-line treatment option for patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC). The trial’s principal investigator, Shun Lu, MD, PhD, said that aumolertinib with platinum-pemetrexed chemotherapy demonstrated a…

*May 2025* The FDA has granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis) for the treatment of adult patients with locally advanced or metastatic, nonsquamous non–small cell lung cancer (NSCLC) harboring high c-MET protein overexpression who have received a prior systemic therapy.1 High c-MET protein overexpression is defined as strong (immunohistochemistry…

*May 2025* MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab, successfully met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint,…

*June 2025* For patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, the treatment landscape is poised for a significant shift. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Helena Yu, MD, presented compelling results from the phase 2b part of the REZILIENT 1 study (NCT04036682),…

*June 2025* Raffaele Califano, MD, of the Christie NHS Foundation Trust and the University of Manchester, discusses outcomes by osimertinib resistance mechanisms in MARIPOSA-2, a study that evaluated the efficacy of the bispecific antibody amivantamab-vmjw plus chemotherapy vs chemotherapy in patients with EGFR-mutant advanced NSCLC after disease progression on osimertinib. Watch video…

*June 2025* The antibody-drug conjugate patritumab deruxtecan (HER3-DXd) did not improve overall survival (OS) compared with platinum-based chemotherapy in patients with EGFR mutation–positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to results from the phase 3 HERTHENA-Lung02 trial (NCT05338970) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual…

*April 2025* Note: The following is an abstract from AACR 2025 presenting data on this new clinical trial, SOLARA (NCT06706076) Outcomes on tyrosine kinase inhibitor (TKI) treatment in EGFR-mutant NSCLC fall short of the durable benefit observed with next-generation targeted therapies in ALK and ROS1-driven NSCLC. We reviewed the chemical structures of 30+ existing…